Quick Answer
Kyverna Therapeutics, Inc. reported Stockholders Equity of $232.28 million for fiscal year 2025.
Kyverna Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $232.28M | -12.9% |
| 2024 | $266.59M | +2129.0% |
| 2023 | -$13.14M | +82.2% |
| 2022 | -$74.00M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $151.95M | -49.8% | -17.6% |
| June 30, 2025 | $184.38M | -44.7% | -17.7% |
| March 31, 2025 | $224.01M | -37.9% | -16.0% |
| December 31, 2024 | $266.59M | +302.9% | -11.9% |
| September 30, 2024 | $302.71M | +370.7% | -9.2% |
| June 30, 2024 | $333.51M | +443.1% | -7.6% |
| March 31, 2024 | $360.99M | +526.6% | +374.7% |
| December 31, 2023 | -$131.40M | -77.6% | -17.5% |
- Kyverna Therapeutics, Inc. showed a decrease of -12.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Kyverna Therapeutics, Inc.’s stockholders equity has grown by 413.9% (from -$74.00 million to $232.28 million).
- The most recent figure is from Kyverna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: